134 related articles for article (PubMed ID: 9218021)
1. Role of PSA and its indices in determining the need for repeat prostate biopsies.
Ukimura O; Durrani O; Babaian RJ
Urology; 1997 Jul; 50(1):66-72. PubMed ID: 9218021
[TBL] [Abstract][Full Text] [Related]
2. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
3. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
[TBL] [Abstract][Full Text] [Related]
5. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
6. Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA levels.
Perachino M; di Ciolo L; Barbetti V; Ardoino S; Vitali A; Introini C; Vigliercio G; Puppo P
Eur Urol; 1997; 32(2):155-9. PubMed ID: 9286645
[TBL] [Abstract][Full Text] [Related]
7. Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
Celhay O; de la Taille A; Salomon L; Doré B; Irani J
BJU Int; 2007 May; 99(5):1028-30. PubMed ID: 17324221
[TBL] [Abstract][Full Text] [Related]
8. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Fowler JE; Bigler SA; Miles D; Yalkut DA
J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
[TBL] [Abstract][Full Text] [Related]
9. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
10. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
12. Variation in patterns of practice in diagnosing screen-detected prostate cancer.
Nam RK; Toi A; Trachtenberg J; Jewett MA; Klotz L; Fleshner N; Bagnell PS; Sweet J; Sugar L; Narod SA
BJU Int; 2004 Dec; 94(9):1239-44. PubMed ID: 15610097
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4-10 ng/ml.
Lodeta B; Benko G; Car S; Filipan Z; Stajcar D; Dujmović T
Acta Clin Croat; 2009 Jun; 48(2):153-5. PubMed ID: 19928413
[TBL] [Abstract][Full Text] [Related]
14. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
[TBL] [Abstract][Full Text] [Related]
15. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
[TBL] [Abstract][Full Text] [Related]
16. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
[TBL] [Abstract][Full Text] [Related]
18. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
19. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
Ohigashi T; Kanao K; Kikuchi E; Nakagawa K; Nakashima J; Marumo K; Murai M
J Urol; 2005 May; 173(5):1541-5. PubMed ID: 15821482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]